drugset / Trial / NCT04993391
AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a phase I/II, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, PK profile and efficacy of JS111 for patients with Non-small cell lung cance. This study is divided into 3 periods: dose escalation stage, dose extension stage, and efficacy extension stage.
Timeline
- Start
- 2021-07-14
- Primary completion
- 2024-02-04
- Completion
- 2024-02-04
Outcome
Outcome not reported
Stopped (Business): “The study was stopped because of a change in the study strategy”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JS111 | Unknown | 40 mg | Oral |
| Subject | JS111 | Unknown | 80 mg | Oral |
| Subject | JS111 | Unknown | 160 mg | Oral |
| Subject | JS111 | Unknown | 240 mg | Oral |
| Subject | JS111 | Unknown | 320 mg | Oral |